Cantor Fitzgerald reiterates Rocket Pharmaceuticals stock rating
Covered in this story
Analyst targets on Rocket Pharmaceuticals Inc
- Goldman Sachs: $2.6 → $4 by Oct 2027 · Neutral via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $RCKT yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Rocket Pharmaceuticals Inc →Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.